Evidence map›Paper›PMID 33961946›Full record

ReviewNeurochemistry international2021

Adenosine kinase: An epigenetic modulator in development and disease.

Madhuvika Murugan, Denise Fedele, David Millner, Enmar Alharfoush, Geetasravya Vegunta, Detlev Boison

Open access · greenAbstract readReview
In one paragraph

Review in Neurochemistry international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Madhuvika MuruganDepartment of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
Denise FedeleDepartment of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
David MillnerDepartment of Neurosurgery, New Jersey Medical School, Rutgers University, Newark, NJ 07102, USA.
Enmar AlharfoushDepartment of Cell Biology and Neuroscience, Rutgers University, New Brunswick, NJ 08901, USA.
Geetasravya VeguntaDepartment of Biology, Albert Dorman Honors College, New Jersey Institute of Technology, Newark, NJ, 07102, USA.
Detlev BoisonDepartment of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA; Department of Neurosurgery, New Jersey Medical School, Rutgers University, Newark, NJ 07102, USA; Brain Health Institute, Rutgers University, Piscataway, NJ 08854, USA. Electronic address: detlev.boison@rutgers.edu.
Rutgers, The State University of New Jersey · USNew Jersey Institute of Technology · US

Funding

The Role of Adenosine in Ketogenic Diet TherapyR01NS065957 · NINDS · TRINITY COLLEGE · PI BOISON, DETLEV, GEIGER, JONATHAN DAVID · 2010 to 2021
$3.9M
Adenosine receptor mediated therapies for SUDEPR01NS103740 · NINDS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI BOISON, DETLEV · 2018 to 2022
$1.7M
NINDS NIH HHS R01 NS065957NINDS NIH HHS R01 NS103740
6 · The paper itself

Abstract

Adenosine kinase (ADK) is the key regulator of adenosine and catalyzes the metabolism of adenosine to 5'-adenosine monophosphate. The enzyme exists in two isoforms: a long isoform (ADK-long, ADK-L) and a short isoform (ADK-short, ADK-S). The two isoforms are developmentally regulated and are differentially expressed in distinct subcellular compartments with ADK-L localized in the nucleus and ADK-S localized in the cytoplasm. The nuclear localization of ADK-L and its biochemical link to the transmethylation pathway suggest a specific role for gene regulation via epigenetic mechanisms. Recent evidence reveals an adenosine receptor-independent role of ADK in determining the global methylation status of DNA and thereby contributing to epigenomic regulation. Here we summarize recent progress in understanding the biochemical interactions between adenosine metabolism by ADK-L and epigenetic modifications linked to transmethylation reactions. This review will provide a comprehensive overview of ADK-associated changes in DNA methylation in developmental, as well as in pathological conditions including brain injury, epilepsy, vascular diseases, cancer, and diabetes. Challenges in investigating the epigenetic role of ADK for therapeutic gains are briefly discussed.

Indexed as

Adenosine KinaseAnimalsBrain InjuriesDNA MethylationEpigenesis, GeneticEpilepsyGene Expression RegulationHumansAdenosine KinaseAdenosine kinaseDevelopmentDNA methylationEpigenetic regulatorEpilepsy

Identifiers

PMID33961946
PMCPMC8178237
OpenAlexW3158061404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.